BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-45@catalystbrief.girapphe.com
DTSTAMP:20261117T061550Z
LAST-MODIFIED:20261117T061550Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: AbbVie — Lutikizumab [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Assess Disease Activity 
 and Safety of Lutikizumab in Adult and Adolescent Participants With Modera
 te to Severe Hidradenitis Suppurativa.\nSource: https://clinicaltrials.gov
 /study/NCT06468228\nhttps://catalystbrief.girapphe.com/e/45?lang=en\nNot i
 nvestment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/45?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
